XEN gel stent ® in the management of glaucoma: preliminary results of a tertiary center

Q4 Medicine

Oftalmologicheskii zhurnal Pub Date : 2023-02-28 DOI:10.31288/oftalmolzh20231913

Rita Vieira, A. Figueiredo, Isabel Sampaio, M. Menéres

{"title":"XEN gel stent ® in the management of glaucoma: preliminary results of a tertiary center","authors":"Rita Vieira, A. Figueiredo, Isabel Sampaio, M. Menéres","doi":"10.31288/oftalmolzh20231913","DOIUrl":null,"url":null,"abstract":"Purpose: To analyze the efficacy and safety of a MIGS device (XEN gel stent ®) in the management of glaucoma in our tertiary center. \nMethods: Retrospective analysis of patients submitted to XEN ® implant alone or combined with cataract surgery. Patients with previous filtering surgeries were included. Intraocular pressure (IOP) was evaluated at 1st week, 1st, 3rd, 6th and 12th months after surgery. BCVA, RNFL thickness and number of antiglaucoma medications were evaluated 1 year after surgery. Early and late complications and need for an additional glaucoma surgery were recorded.\nResults: Thirty-four eyes from 28 patients were included. The main diagnosis was primary open angle glaucoma (POAG) (58.8%).\nIOP decreased from 20.5±4.9 mmHg to 15.4±4.1 mmHg 1 year after surgery (p<0.001). There was also a decrease in the number of antiglaucoma medications, from 3.6±0.6 to 0.6±0.7 (p<0.001). BCVA increased from 0.57±0.30 to 0.87±0.18 in the combined surgery group (p=0.03). RNFL thickness remained stable (p=0.558).\nHypotony occurred in 2 eyes (5.9%). Two eyes (5.9%) needed another glaucoma surgery in the 1st year of follow-up.\nConclusion: According to our results, XEN® alone or combined with phacoemulsification showed to be effective in IOP reduction, with few complications, as a primary surgery or even in eyes with previous filtering surgeries.","PeriodicalId":19419,"journal":{"name":"Oftalmologicheskii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oftalmologicheskii zhurnal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31288/oftalmolzh20231913","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To analyze the efficacy and safety of a MIGS device (XEN gel stent ®) in the management of glaucoma in our tertiary center. Methods: Retrospective analysis of patients submitted to XEN ® implant alone or combined with cataract surgery. Patients with previous filtering surgeries were included. Intraocular pressure (IOP) was evaluated at 1st week, 1st, 3rd, 6th and 12th months after surgery. BCVA, RNFL thickness and number of antiglaucoma medications were evaluated 1 year after surgery. Early and late complications and need for an additional glaucoma surgery were recorded. Results: Thirty-four eyes from 28 patients were included. The main diagnosis was primary open angle glaucoma (POAG) (58.8%). IOP decreased from 20.5±4.9 mmHg to 15.4±4.1 mmHg 1 year after surgery (p<0.001). There was also a decrease in the number of antiglaucoma medications, from 3.6±0.6 to 0.6±0.7 (p<0.001). BCVA increased from 0.57±0.30 to 0.87±0.18 in the combined surgery group (p=0.03). RNFL thickness remained stable (p=0.558). Hypotony occurred in 2 eyes (5.9%). Two eyes (5.9%) needed another glaucoma surgery in the 1st year of follow-up. Conclusion: According to our results, XEN® alone or combined with phacoemulsification showed to be effective in IOP reduction, with few complications, as a primary surgery or even in eyes with previous filtering surgeries.

查看原文本刊更多论文

XEN凝胶支架®治疗青光眼：三级中心的初步结果

目的：分析MIGS装置（XEN凝胶支架®）在我们三级中心治疗青光眼的疗效和安全性。方法：对接受XEN®植入物单独或联合白内障手术的患者进行回顾性分析。包括既往做过过滤手术的患者。术后第1周、第1、第3、第6和第12个月评估眼压。术后1年评估BCVA、RNFL厚度和抗青光眼药物的数量。记录了早期和晚期并发症以及需要进行额外青光眼手术的情况。结果：28例患者共34眼。主要诊断为原发性开角型青光眼（POAG）（58.8%），术后1年眼压从20.5±4.9 mmHg降至15.4±4.1 mmHg（p<0.001），从3.6±0.6增加到0.6±0.7（p＜0.001）。联合手术组的BCVA从0.57±0.30增加到0.87±0.18（p＝0.03）。RNFL厚度保持稳定（p＝0.558）。2眼（5.9%）出现低血压。2眼在随访的第一年需要再次进行青光眼手术。结论：根据我们的结果，XEN®单独使用或与超声乳化术联合使用，作为一种初级手术，甚至对有过过滤手术的眼睛来说，都能有效降低眼压，并发症很少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oftalmologicheskii zhurnal Medicine-Ophthalmology

CiteScore

0.40

自引率

0.00%

发文量

期刊介绍： Journal of Ophthalmology (Ukraine) contains articles on eye diseases diagnosis and treatment, eye care, eye diseases prevention, history of ophthalmology, organization of eye care to population, technical equipment problems. It is committed to publishing original scientific researches and review articles on theory and practice of Ukrainian and foreign ophthalmology, cases, reviews, inventions, historical and medical reviews. It contains peer-reviews of books on ophthalmology, articles on activity of ophthalmologic societies, congresses and conferences chronicles. Journal is designed to ophthalmologists and scientific researchers in the field of vision physiology and eye diseases clinic.